How to Get Addyi (Flibanserin) in Nebraska

What Addyi Is and Why the Prescription Process Is Different

Flibanserin, sold as Addyi, is a non-hormonal, centrally acting serotonin 1A agonist and serotonin 2A antagonist approved by the FDA on August 18, 2015, specifically for acquired, generalized HSDD in premenopausal women. The condition is defined as low sexual desire that causes personal distress and is not explained by another medical condition, a relationship problem, or medication side effects. Sprout Pharmaceuticals' REMS program governs every Addyi prescription in the United States.

The REMS (Risk Evaluation and Mitigation Strategy) requirement is the single biggest reason obtaining Addyi differs from getting a standard oral contraceptive or antidepressant. Because flibanserin causes severe hypotension and syncope when combined with alcohol, the FDA mandated that every prescriber complete a certified training module before writing a single script. Every dispensing pharmacy must also be REMS-certified. The FDA's Addyi REMS page lists the full prescriber and pharmacy enrollment requirements.

The clinical evidence supporting approval comes primarily from three Phase 3 trials. The BEGONIA trial (PubMed PMID 24628797), a randomized, double-blind, placebo-controlled study of 1,378 premenopausal women, showed that flibanserin 100 mg nightly produced statistically significant improvements in the number of satisfying sexual events (SSEs), Female Sexual Function Index desire domain scores, and Female Sexual Distress Scale-Revised scores compared to placebo over 24 weeks (P<0.001 for all co-primary endpoints). Mean SSEs per month increased by 2.5 in the flibanserin group versus 1.5 in the placebo group. That 1.0-event-per-month difference over placebo reflects the modest but clinically meaningful effect size the FDA's review committee weighted alongside the unmet need in this population.

The FDA label states: "The efficacy of ADDYI was evaluated in three 24-week, randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD." Understanding that narrow indication matters for Nebraska clinicians conducting the prescriber certification, because any off-label use (postmenopausal women, men) falls outside REMS-covered training.

Nebraska Telehealth Rules That Make Remote Prescribing Legal

Nebraska permits telehealth prescribing. Full stop.

Nebraska Revised Statute 71-8503 defines telehealth broadly as the delivery of health-care services using electronic information and telecommunications technologies. The statute does not restrict telehealth to audio-visual encounters for Schedule-exempt medications like flibanserin. A licensed Nebraska physician (MD or DO), advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) acting under a physician delegation agreement can each initiate a flibanserin prescription after a synchronous telehealth encounter during which they complete a clinically adequate evaluation of the patient.

The Nebraska Department of Health and Human Services affirms that APRNs in Nebraska have full practice authority, meaning a nurse practitioner does not require physician oversight to write a prescription. This is relevant because several national telehealth platforms now specifically deploy NPs for HSDD evaluations, and those prescriptions carry the same legal weight in Nebraska as an MD prescription.

One practical note: the prescriber must complete Sprout's REMS training regardless of their credential type. The REMS does not differentiate between MD, NP, and PA. The FDA confirms REMS enrollment requirements apply to all prescriber types.

For patients using out-of-state telehealth platforms, the prescribing provider must hold either a Nebraska medical license or a qualifying interstate license under the Interstate Medical Licensure Compact (IMLC). Nebraska joined the IMLC in 2016, so physicians licensed under the compact can legally prescribe to Nebraska residents.

Step-by-Step: How to Get a Flibanserin Prescription in Nebraska

Getting Addyi in Nebraska follows a predictable sequence. Each step has a time cost, so mapping them out in advance helps.

Step 1. Confirm you meet the FDA-labeled indication.

Addyi is approved only for acquired, generalized HSDD in premenopausal women. "Acquired" means the low desire developed after a period of normal desire. "Generalized" means it occurs across partners and situations, not just in specific circumstances. Your prescriber will screen for this using validated tools like the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). A score of 26.55 or below on the FSFI is the commonly cited threshold for sexual dysfunction, though clinical judgment governs the final diagnosis.

Step 2. Find a REMS-certified prescriber in Nebraska.

You have three options. First, your own OB-GYN or primary care physician may already be REMS-certified; call their office and ask directly. Second, you can search Sprout Pharmaceuticals' certified prescriber locator at the Addyi website. Third, and most efficiently for many Nebraska residents outside Omaha and Lincoln, you can book a telehealth consultation with a platform that employs REMS-certified prescribers.

Telehealth platforms currently serving Nebraska for HSDD evaluations include national operators that hold Nebraska prescriber licensure. A standard telehealth intake for flibanserin takes 20 to 40 minutes and covers sexual history, medication reconciliation (critically, any CYP3A4 inhibitors or CNS depressants), alcohol use, and hepatic history.

Step 3. Get baseline labs.

Liver function tests (LFTs) including AST, ALT, and total bilirubin are required before starting flibanserin. The drug is contraindicated in patients with hepatic impairment of any severity because reduced CYP2C19 metabolism markedly elevates flibanserin plasma concentrations and worsens hypotension risk. The FDA prescribing information is explicit: "ADDYI is contraindicated in patients with hepatic impairment."

Most Nebraska telehealth platforms either accept recent lab results (drawn within 90 days) or direct patients to a local Quest Diagnostics, LabCorp, or hospital outpatient lab for a standing order the telehealth provider can issue electronically. Turnaround in Nebraska urban centers is typically 24 to 48 hours.

Step 4. Receive the electronic prescription.

Once labs are reviewed and the REMS counseling is completed, the prescriber sends an electronic prescription to a REMS-certified pharmacy. This can be a national mail-order pharmacy or a local Nebraska retail pharmacy that has enrolled in the REMS program. Not every Walgreens or Hy-Vee pharmacy in Nebraska is REMS-certified; you or your prescriber should confirm certification before routing the script.

Step 5. Pharmacy dispense and delivery.

For mail-order, shipping to a Nebraska address typically takes 3 to 7 business days from prescription verification. Local Nebraska pharmacies certified under REMS can dispense same-day or next-day. A 30-day supply of brand-name Addyi lists at approximately $400 to $800 without insurance, though Sprout's savings card can reduce out-of-pocket cost to as low as $99 per month for eligible commercially insured patients.

Labs and Clinical Screening Required Before Your First Dose

Pre-prescribing screening for flibanserin in Nebraska involves both laboratory and clinical components.

Laboratory requirements:

• Comprehensive or basic metabolic panel to assess hepatic function (AST, ALT, alkaline phosphatase, total bilirubin)
• No specific renal function test is required by the label, though clinicians may order a BMP as part of a broader workup

Clinical screening questions your provider will ask:

Does the patient take a moderate or strong CYP3A4 inhibitor? Drugs including fluconazole, ketoconazole, clarithromycin, erythromycin, grapefruit-containing products, and dozens of others inhibit the primary metabolic pathway for flibanserin, raising plasma levels enough to produce severe hypotension and syncope. A medication reconciliation review is non-negotiable. NIH's drug interaction database outlines CYP3A4 inhibitor classes in detail.

Does the patient take a CNS depressant? Benzodiazepines, opioids, diphenhydramine, and similar agents compound the CNS depression risk from flibanserin.

Does the patient consume alcohol? The REMS patient-provider agreement specifically documents alcohol use counseling. Zero alcohol within 2 hours before the bedtime dose and 6 hours after is the required guidance. The FDA's 2015 labeling change following a dedicated pharmacokinetic-pharmacodynamic alcohol interaction study showed that even two standard drinks increased the rate of severe hypotension events from roughly 4% (flibanserin alone) to approximately 29%. That number should not be softened.

Is the patient postmenopausal? Addyi is not FDA-approved for postmenopausal women, and REMS certification covers premenopausal use only.

Insurance Coverage and Cost in Nebraska

Nebraska Medicaid does not cover flibanserin. This is consistent with the majority of state Medicaid programs nationally, which classify Addyi as a non-essential drug for coverage purposes.

Private insurance coverage in Nebraska is variable. Some BCBS Nebraska, Medica, and UnitedHealthcare commercial plans have added Addyi to formulary tiers, but prior authorization (PA) is almost universally required. The documentation that Nebraska commercial plans typically request for PA includes:

1. Diagnosis of HSDD using ICD-10 code F52.0 (hypoactive sexual desire dysfunction)
2. Confirmation of premenopausal status (FSH level, clinical history, or provider attestation)
3. Documentation that non-pharmacological interventions (sex therapy, couples counseling, or psychotherapy) were offered or attempted
4. Provider attestation that no contraindicated medications are being co-prescribed
5. REMS prescriber certification number

PA denials in Nebraska can be appealed. The appeal pathway typically requires a peer-to-peer review between the prescribing clinician and the plan's medical director, at which point citing the BEGONIA trial data and the FDA-approved indication directly tends to strengthen the case.

For patients without insurance coverage, Sprout Pharmaceuticals' current savings program can bring costs down, and GoodRx-type discount platforms sometimes list flibanserin at reduced rates at specific Nebraska pharmacies. Prices vary by zip code and change frequently, so checking the platform directly at the time of prescribing gives the most accurate figure.

503A Compounding Pharmacies in Nebraska and Flibanserin

Nebraska is one of the states where 503A compounding pharmacies are licensed and authorized to compound flibanserin for individual patients with a valid prescription. A 503A pharmacy (as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act) compounds medications for specific patients based on a prescriber's order, and it may prepare flibanserin in non-commercial dosage forms if a clinically appropriate reason exists.

Why would a patient or prescriber consider a compounded formulation? The most common reason is cost. Compounded flibanserin from a licensed 503A pharmacy can cost significantly less than brand-name Addyi. A second reason is dosage flexibility; some clinicians titrate patients who experience significant side effects at 100 mg on a lower dose (e.g., 50 mg nightly) while monitoring response, and compounding allows that.

The REMS does not explicitly extend to 503A-compounded flibanserin, which creates an important regulatory nuance. The prescriber writing a script for compounded flibanserin is still expected to have completed REMS training because the safety concerns around alcohol interaction and CYP3A4 inhibitor interaction are pharmacological, not brand-specific. Nebraska's State Board of Pharmacy oversees 503A pharmacies, and any pharmacy compounding flibanserin must comply with USP Chapter 795 non-sterile compounding standards. FDA's guidance on 503A compounding outlines the federal framework.

Patients should verify that a Nebraska 503A pharmacy is currently in good standing with the Nebraska State Board of Pharmacy before transferring a prescription for compounding.

Transferring an Existing Addyi Prescription to Nebraska

Patients who move to Nebraska with an existing Addyi prescription from another state face a specific set of logistics.

First, the current out-of-state prescription remains valid if it was written by a licensed prescriber and was transmitted to a REMS-certified pharmacy in the original state. However, an out-of-state pharmacy cannot ship a controlled substance across state lines, and while flibanserin is not a controlled substance, the REMS-certified pharmacy in the original state may still be restricted to shipping within that state's regulatory framework depending on their licensure.

The cleanest transfer path: request that your out-of-state prescriber send a new electronic prescription to a REMS-certified Nebraska pharmacy or mail-order pharmacy that services Nebraska. Many national telehealth platforms that originally prescribed for you can route the renewal to a Nebraska-licensed pharmacy without requiring a new full evaluation, provided you are within the refill window and no significant clinical changes have occurred.

If you are switching to a new Nebraska-based prescriber, they will need to conduct their own clinical evaluation to document the HSDD diagnosis and confirm REMS requirements before prescribing. They cannot simply "take over" a prescription without their own documentation.

The following decision framework outlines how Nebraska prescribers should triage new HSDD patients requesting flibanserin:

HealthRX Nebraska Flibanserin Prescribing Decision Framework

1. Confirm premenopausal status (clinical history, FSH if unclear).
2. Administer FSFI and FSDS-R. FSFI desire subscore of 3.3 or below plus FSDS-R score of 11 or above supports HSDD diagnosis.
3. Rule out secondary causes: hypothyroidism (TSH), hypogonadism (total testosterone, though not required by label), depression (PHQ-9), relationship dysfunction (brief validated screen).
4. Review full medication list for CYP3A4 inhibitors and CNS depressants. If present, do not prescribe.
5. Assess alcohol use with AUDIT-C. If score suggests hazardous drinking, counsel and consider deferring until sobriety is achieved.
6. Order LFTs. Hold prescription pending normal results.
7. Complete Sprout REMS prescriber training if not already certified.
8. Document REMS counseling in the patient's chart, including alcohol restriction acknowledgment.
9. Send electronic prescription to a Nebraska REMS-certified pharmacy or national mail-order REMS pharmacy.
10. Schedule 4-week follow-up to assess tolerability and 12-week follow-up to evaluate efficacy before continuing past the initial supply.

What to Expect in the First 8 Weeks on Addyi

Flibanserin's mechanism requires consistent nightly dosing to produce benefit. Patients should understand the timeline.

Weeks 1 to 2: The most common side effects appear early. Dizziness, somnolence, nausea, and fatigue affect approximately 10 to 20% of patients in clinical trials. The FDA prescribing information lists dizziness (11%), somnolence (11%), nausea (10%), and fatigue (9%) as the most frequent adverse events versus placebo. Taking the pill at bedtime (not earlier in the evening) minimizes the impact of these effects during waking hours.

Weeks 3 to 4: Most tolerability issues resolve or become manageable. This is the window for the first follow-up call with the prescriber.

Weeks 8 to 12: Clinically meaningful improvement in SSEs and desire scores, if it is going to occur, typically becomes apparent in this window. The FDA label advises evaluating efficacy at 8 weeks and discontinuing in patients who do not experience improvement by that point, since continued treatment without benefit exposes patients to ongoing side effect risk without reward.

The North American Menopause Society (NAMS) 2022 position statement on sexual dysfunction in women notes: "Flibanserin 100 mg taken at bedtime is a reasonable option for premenopausal women with HSDD who have been counseled about the alcohol restriction and drug interaction risks." That statement reflects the current clinical standard of care against which Nebraska prescribers are measured. NAMS position on sexual dysfunction.

Alcohol Restriction: The Safety Rule Nebraska Patients Must Understand

No clinical discussion of flibanserin is complete without addressing the alcohol restriction in plain language.

The FDA's 2015 post-marketing requirement study enrolled healthy volunteers to measure the pharmacodynamic interaction between flibanserin and alcohol under controlled conditions. At three different alcohol doses (one standard drink, two standard drinks, four standard drinks), co-administration with flibanserin 100 mg produced clinically significant drops in standing systolic blood pressure. At the two-drink dose, 6 of 23 subjects (approximately 25%) experienced a hypotensive event meeting protocol-defined criteria.

Do not drink alcohol for at least 2 hours before taking your bedtime dose and for at least 6 hours after waking. Given that most patients take flibanserin at roughly 10 p.m. and wake at roughly 6 a.m., the practical guidance is: no alcohol after approximately 8 p.m. on any night you take the medication.

Nebraska patients who participate in social drinking should discuss this realistically with their prescriber. The REMS counseling document the patient signs is a legal acknowledgment of understanding this restriction, not just a formality.